Compounded tirzepatide and Zepbound are not the same product. Zepbound is an FDA-approved brand-name tirzepatide medication, while compounded tirzepatide is prepared by a compounding pharmacy when prescribed and is not FDA-approved. At Forva, standard compounded tirzepatide can be as low as $239 every 4 weeks (about $259 per calendar month), while provider-supervised tirzepatide microdose plans can be as low as $139 every 4 weeks (about $151 per calendar month) on a 48-week prepaid plan.
How much do compounded tirzepatide and Zepbound cost in 2026?
Forva's compounded tirzepatide starts at $299 every 4 weeks (about $324 per calendar month) on the standard 4-week plan. Longer prepaid options reduce the effective cost of each 4-week cycle, and a provider-supervised tirzepatide microdose plan can cost as little as $139 every 4 weeks if prescribed.
| Option | 2026 pricing |
|---|---|
| Forva standard compounded tirzepatide, 4-week plan | $299 every 4 weeks (about $324 per calendar month) |
| Forva standard, 12-week prepaid | $807 total, $269 every 4 weeks (about $291 per calendar month) |
| Forva standard, 24-week prepaid | $1,554 total, $259 every 4 weeks (about $281 per calendar month) |
| Forva standard, 48-week prepaid | $2,868 total, $239 every 4 weeks (about $259 per calendar month) |
| Forva microdose, 4-week plan | $229 every 4 weeks (about $248 per calendar month) |
| Forva microdose, 12-week prepaid | $537 total, $179 every 4 weeks (about $194 per calendar month) |
| Forva microdose, 24-week prepaid | $954 total, $159 every 4 weeks (about $172 per calendar month) |
| Forva microdose, 48-week prepaid | $1,668 total, $139 every 4 weeks (about $151 per calendar month) |
| Zepbound 2.5 mg self-pay | Starting at $299/month |
| Zepbound 5 mg self-pay | Starting at $399/month |
| Zepbound 7.5 mg and higher doses | Starting at $449/month when refilled within 45 days |
As of September 2026, Lilly advertises these self-pay prices through LillyDirect. Terms apply, and the higher-dose price requires refilling within 45 days; otherwise Lilly's regular prices apply.
Forva's compounded-plan prices include the provider review, medication if prescribed, shipping, and ongoing provider support. There is no separate membership fee on compounded plans. Compounded plans bill every 4 weeks, which works out to 13 billing cycles a year rather than 12 calendar months.
What is the difference between compounded tirzepatide and Zepbound?
The most important difference is FDA approval.
Zepbound is an FDA-approved tirzepatide medication manufactured by Eli Lilly. Its manufacturing, labeling, indications, dosage forms, and prescribing information have undergone FDA review.
Compounded tirzepatide is prepared by a compounding pharmacy when prescribed for an individual patient. It is not FDA-approved, and the FDA does not review compounded products for safety, effectiveness, or quality before marketing.
Compounded tirzepatide is not Zepbound, is not generic Zepbound, and should not be described as an FDA-approved equivalent.
How much is Forva's tirzepatide microdose option?
Forva's provider-supervised tirzepatide microdose plans can cost as little as $139 every 4 weeks on the 48-week prepaid plan, with $1,668 paid upfront.
Other microdose options include $229 every 4 weeks, $537 for 12 weeks, and $954 for 24 weeks. The prepaid 12-week and 24-week options work out to $179 and $159 every 4 weeks.
A microdose treatment plan uses a lower-dose approach and is not simply standard tirzepatide sold at a discount.
A licensed provider determines whether a microdose approach is medically appropriate. Depending on the patient, the provider may instead recommend another compounded plan, an FDA-approved brand-name medication, or a different treatment approach.
Does Forva only prescribe compounded tirzepatide?
No. Forva can also support patients who prefer an FDA-approved brand-name GLP-1 medication.
If a patient would rather use a brand-name medication such as Zepbound, a licensed Forva provider can evaluate whether that medication is appropriate. If the patient qualifies and the provider decides to prescribe it, the prescription is sent to LillyDirect, Eli Lilly's direct-to-patient service, which routes prescriptions to licensed third-party dispensing pharmacies. The patient pays Lilly's self-pay price for the medication directly ($299 to $449 a month depending on dose, as of September 2026, with each refill required within 45 days of the previous delivery), and Forva charges a $99/month membership that covers the provider review and ongoing care. The membership does not include medication.
Foundayo, Lilly's oral option, is available on the same membership if prescribed (from $149/mo as of September 2026).
That flexibility means patients do not have to choose Forva solely because they want compounded medication.
A self-pay patient may prefer the predictable cost of a compounded plan. Another patient may specifically prefer an FDA-approved product or may simply feel more comfortable with the brand-name option, purchased directly from the manufacturer at its self-pay price.
In either situation, the medication decision belongs to the licensed provider.
Patients can review Forva's available weight-loss options.
Which option can cost less without insurance?
Forva's compounded tirzepatide plans can have a lower effective cost per calendar month than current Zepbound self-pay pricing, although the products are not equivalent.
Forva's 48-week standard compounded tirzepatide plan works out to $239 every 4 weeks. Its provider-supervised microdose plan can be as low as $139 every 4 weeks on the 48-week prepaid option if prescribed.
Lilly currently advertises Zepbound starting at $299 per month for the 2.5 mg starting dose, $399 for 5 mg, and $449 for higher doses when the refill conditions are met.
That does not mean compounded tirzepatide should be considered a substitute that is medically or therapeutically equivalent to Zepbound. FDA approval status and the patient's individual medical circumstances matter.
For an eligible patient paying entirely out of pocket, however, Forva's compounded options may offer a lower and more predictable cost per calendar month.
Can insurance make Zepbound cheaper?
Yes. Insurance coverage and manufacturer savings programs can make Zepbound considerably less expensive for some patients.
Lilly advertises savings opportunities for eligible commercially insured patients, and actual out-of-pocket costs depend on the patient's coverage and program eligibility.
Forva's compounded GLP-1 plans are self-pay. Insurance is not needed or accepted for those compounded plans.
Forva accepts FSA and HSA cards. Whether a purchase counts as a qualified medical expense is determined by the patient's plan administrator.
For patients who want brand-name treatment instead, Forva's licensed providers can evaluate and prescribe Zepbound when medically appropriate and send the prescription to LillyDirect. The patient pays Lilly's self-pay price for the medication directly, plus Forva's $99/month membership for provider review and ongoing care. That is Lilly's self-pay price, paid to the dispensing pharmacy. Both paths are self-pay. Forva does not bill or accept insurance, and the manufacturer's pharmacy does not bill insurance for these products either, so the price is the same regardless of a patient's coverage.
What does Forva's compounded tirzepatide price include?
Forva's advertised compounded tirzepatide price includes the provider review, medication if prescribed, shipping, and ongoing provider support.
There is no separate membership fee on compounded plans.
Treatment begins with a short online medical intake. A licensed provider reviews the patient's information and determines whether GLP-1 treatment is medically appropriate.
If compounded treatment is prescribed, the medication is prepared by a licensed U.S. compounding pharmacy and shipped discreetly to the patient's door.
If the patient prefers a brand-name medication instead, the provider can consider that option and, if prescribed, send the prescription to LillyDirect, where the patient pays Lilly's self-pay price directly. Forva charges a $99/month membership on that path.
If the provider determines medication treatment is not appropriate, the patient is not charged for compounded medication.
Patients can start Forva's online weight-loss evaluation.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not FDA-approved.
The FDA says compounded GLP-1 drugs do not undergo agency review for safety, effectiveness, or quality before marketing. The FDA recommends that patients receive prescriptions from licensed healthcare providers and fill prescriptions through appropriately licensed pharmacies.
The FDA also warns consumers to be cautious of telehealth companies that claim compounded GLP-1 medications are the same as FDA-approved medications.
Zepbound is FDA-approved. Compounded tirzepatide is not.
Forva's providers determine whether compounded medication, an FDA-approved brand-name medication, or another treatment is appropriate for each patient. Results vary.
How should a patient choose between compounded tirzepatide and Zepbound?
The choice should consider FDA approval, insurance coverage, actual out-of-pocket cost, treatment preferences, and the licensed provider's recommendation.
Someone who specifically wants an FDA-approved brand-name medication may prefer Zepbound. Forva's licensed providers can prescribe Zepbound when the patient qualifies and it is medically appropriate, then send the prescription to LillyDirect; the patient pays Lilly's self-pay price for the medication directly, plus Forva's $99/month membership.
A self-pay patient who is comfortable considering compounded medication and prioritizes predictable pricing may find Forva's compounded plans attractive. Standard tirzepatide can be as low as $239 every 4 weeks, and provider-supervised tirzepatide microdose plans can be as low as $139 every 4 weeks on the 48-week prepaid option.
Forva therefore gives eligible patients access to both pathways rather than requiring everyone to use the same type of medication.
This article is for general information and is not medical advice. Eligibility and treatment decisions are made by a licensed provider.